U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Ho C, Adcock L. Inpatient and Outpatient Treatment Programs for Substance Use Disorder: A Review of Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Nov 7.

Cover of Inpatient and Outpatient Treatment Programs for Substance Use Disorder: A Review of Clinical Effectiveness and Guidelines

Inpatient and Outpatient Treatment Programs for Substance Use Disorder: A Review of Clinical Effectiveness and Guidelines [Internet].

Show details

Key Findings

For patients with alcohol use disorders, better detoxification completion an d abstinence rates, and similar adverse event rates, were found in outpatient care compared to inpatient care in a couple of studies with short follow -up periods (one to two months). One study with a longer follow-up period found inpatients consumed less alcohol than outpatients in the year after entering treatment. In patients with severe alcohol dependence, data from one study found initial but decreasing benefit of inpatient over outpatient care across time in alcohol abstinence. For patients with substance use disorders, data from one study showed inpatients are more likely to complete treatment than outpatients. The small number of studies found and their heterogeneity in design and reported outcomes cautioned the interpretation of the findings.

The evidence-based guidelines from British Columbia Ministry of Health on opioids use disorder recommend that withdrawal management, if needed, can be provided more safely in an outpatient setting rather than in an inpatient setting in most patients. For patients who wish to avoid long-term opioid agonist treatment, supervised slow (longer than one month) outpatient or residential opioid agonist taper can be provided rather than rapid (less than one week) inpatient opioid agonist taper.

Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK507690

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (718K)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...